Objective: There is considerable evidence to suggest that the abuse of illicit drugs, particularly cannabis and methamphetamine, has aetiological roles in the pathogenesis of psychosis and schizophrenia. Factors that may increase susceptibility to the propsychotic effects of these drugs include the age at which the abuse starts as well as family history of genetic polymorphisms relevant to the pathophysiology of this disorder. However, the neurobiological mechanisms involved in drug abuse-associated psychosis remain largely unclear.
Methods And Results: This paper presents an overview of the available evidence, including clinical, animal model, and molecular studies, with a focus on brain regions and neurotransmitters systems, such as dopamine and glutamate, previously implicated in psychosis.
Conclusion: It is clear that further studies are urgently needed to provide a greater insight into the mechanisms that mediate the long-term and neurodevelopmental effects of cannabis and methamphetamine. A dialogue between basic science and clinical research may help to identify at-risk individuals and novel pathways for treatment and prevention.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/0004867412455232 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Patient factors associated with treatment completion in a 12-week inpatient dual diagnosis treatment program.
Australas Psychiatry
January 2025
Monash University, Melbourne, VIC, Australia.
Objective: To identify whether mental health wellbeing, age, gender or recent substance use pattern affected completion rates of a dual diagnosis inpatient program.
Method: This retrospective cohort study reviewed medical records of patients admitted between October 2018 and December 2021 of Westside Lodge, a dual diagnosis inpatient program. Demographic information, mental health screening tool results (BASIS-24) and self-reported substance use data were accessed from the patients' electronic medical records.
Three-Month Polysubstance Use Patterns Among People Enrolled in Outpatient Treatment for Methamphetamine Use.
Subst Use Misuse
January 2025
National Centre for Youth Substance Use Research (NCYSUR), School of Psychology, The University of Queensland, Brisbane, Australia.
Background: Polysubstance use is common among people who use methamphetamine. This prospective study examined the three-month polysubstance use profiles among people enrolled in outpatient treatment for methamphetamine use and associated substance use, mental health, and treatment correlates.
Method: The present study used routinely collected client-reported outcome measures data from = 1,507 clients enrolled in outpatient treatment who reported methamphetamine as their primary drug of concern ( = 34.
Technology-Based Interventions for Substance Use Treatment Among People Who Identify as African American or Black, Hispanic or Latino, and American Indian or Alaska Native: Scoping Review.
J Med Internet Res
December 2024
Center for Technology and Behavioral Health, Geisel School of Medicine, Dartmouth College, Lebanon, NH, United States.
Background: In the United States, racial and ethnic disparities in substance use treatment outcomes are persistent, especially among underrepresented minority (URM) populations. Technology-based interventions (TBIs) for substance use treatment show promise in reducing barriers to evidence-based treatment, yet no studies have described how TBIs may impact racial or ethnic health equity.
Objective: This study explored whether TBIs in substance use treatment research promote health equity among people who identify as African American or Black, Hispanic or Latino, and American Indian or Alaska Native through their inclusion in research.
Comparative Effectiveness of Buprenorphine/Naloxone and Methadone on Methamphetamine/Amphetamine Use Among People with Opioid Use Disorder in Canada.
Subst Use Addctn J
November 2024
British Columbia Centre on Substance Use, Vancouver, BC, Canada.
Article Synopsis
- The study investigates the impact of opioid agonist therapy (OAT) on methamphetamine and amphetamine use among individuals with opioid use disorder (OUD) in Canada, comparing buprenorphine/naloxone and methadone.
- Conducted over 24 weeks, data from a pan-Canadian trial highlighted that both treatments showed no significant effect on reducing methamphetamine/amphetamine use, as assessed through drug testing and self-reporting.
- Despite methamphetamine/amphetamine use being prevalent among participants, results indicated that neither treatment method led to notable changes in their usage patterns throughout the study period.
Enriching ultra-high risk for psychosis cohorts based on accumulated exposure to environmental risk factors for psychotic disorders.
Psychol Med
November 2024
Orygen, Parkville, Melbourne, VIC 3052, Australia.
Background And Hypothesis: Transition to psychosis rates within ultra-high risk (UHR) services have been declining. It may be possible to 'enrich' UHR cohorts based on the environmental characteristics seen more commonly in first-episode psychosis cohorts. This study aimed to determine whether transition rates varied according to the accumulated exposure to environmental risk factors at the individual (migrant status, asylum seeker/refugee status, indigenous population, cannabis/methamphetamine use), family (family history or parental separation), and neighborhood (population density, social deprivation, and fragmentation) level.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!